Headache recurrence as a criterion for assessing efficacy of triptans: A perspective

Headache

Volumn 42, Issue 1, 2002, Pages 70-79

  Aurora, Sheena K ^a,b  

^a Swedish Headache Center   (United States)

^b SWEDISH MEDICAL CENTER   (United States)

Author keywords

5 HT1B 1D agonist; Headache recurrence; Migraine; Triptan

Indexed keywords

DIHYDROERGOTAMINE; NAPROXEN; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RIZATRIPTAN; SEROTONIN AGONIST; SUMATRIPTAN; TOLFENAMIC ACID; ZOLMITRIPTAN;

CLINICAL FEATURE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; HEADACHE; HUMAN; MIGRAINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; TREATMENT FAILURE;

HEADACHE; HUMANS; RECURRENCE; SEROTONIN AGONISTS; TREATMENT OUTCOME;

EID: 0036166605     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4610.2002.02016.x     Document Type: Review

References (34)

1. Migraine in the United States: A review of epidemiology and health care use
2. American Migraine Study II: Prevalence, burden and health care utilization for migraine in the United States
3. The scientific basis of medication choice in symptomatic migraine treatment
4. How to assess and compare drugs in the management of migraine: Success rates in terms of response and recurrence
5. Efficacy definitions for migraine studies
6. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine
7. Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine
8. Randomized, double-blind, placebo-controlled comparison of oral naratriptan and oral sumatriptan in the acute treatment of migraine
9. Zolmitriptan, a 5-HT 1B/1D receptor agonist for the acute oral treatment of migraine: A multicentre, dose-range finding study
10. A comparison of the efficacy, safety and tolerability of naratriptan and sumatriptan
11. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine
12. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study
13. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study
14. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: Defining the optimum doses of oral sumatriptan
15. High efficacy and low frequency of headache recurrence after oral sumatriptan
16. Oral sumatriptan in preventing headache recurrence after treatment of migraine attacks with subcutaneous sumatriptan
17. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study
18. Oral sumatriptan in the acute treatment of migraine and migraine recurrence in general practice
19. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine
20. Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study
21. Oral rizatriptan versus oral sumatriptan: A direct comparative study in the acute treatment of migraine
22. 1D receptor agonist in the acute oral treatment of migraine: A double-blind, placebo-controlled, doserange finding study
23. Issues relating to the assessment of migraine recurrence following triptan therapy
24. Would any acute treatment for migraine demonstrate recurrence?
25. Evaluating specific acute headache therapies: Recurrence and tolerability
26. Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response
27. Risk factors for headache recurrence after sumatriptan: A study in 366 migraine patients
28. Low migraine headache recurrence with naratriptan: Clinical parameters related to recurrence
29. Summing-up
30. Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine
31. 24-Hour sustained pain free status after rizatriptan and other triptans: A comparison
32. The efficacy of subcutaneous sumatriptan in the treatment of recurrence of migraine headache
33. Tolfenamic acid decreases migraine recurrence when used with sumatriptan
34. Naproxen sodium decreases migraine recurrence when administered with sumatriptan